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IRS4, a novel modulator of BMP/
Smad and Akt signalling during 
early muscle differentiation
Gina Dörpholz1, Arunima Murgai1,2,3, Jerome Jatzlau1,2, Daniel Horbelt1, Mohammad 
Poorgholi Belverdi1, Christina Heroven1, Isabelle Schreiber1,2, Gisela Wendel1, Karen 
Ruschke1, Sigmar Stricker1,2,3 & Petra Knaus1,2
Elaborate regulatory networks of the Bone Morphogenetic Protein (BMP) pathways ensure precise 
signalling outcome during cell differentiation and tissue homeostasis. Here, we identified IRS4 as a 
novel regulator of BMP signal transduction and provide molecular insights how it integrates into the 
signalling pathway. We found that IRS4 interacts with the BMP receptor BMPRII and specifically targets 
Smad1 for proteasomal degradation consequently leading to repressed BMP/Smad signalling in C2C12 
myoblasts while concomitantly activating the PI3K/Akt axis. IRS4 is present in human and primary 
mouse myoblasts, the expression increases during myogenic differentiation but is downregulated upon 
final commitment coinciding with Myogenin expression. Functionally, IRS4 promotes myogenesis 
in C2C12 cells, while IRS4 knockdown inhibits differentiation of myoblasts. We propose that IRS4 is 
particularly critical in the myoblast stage to serve as a molecular switch between BMP/Smad and Akt 
signalling and to thereby control cell commitment. These findings provide profound understanding of 
the role of BMP signalling in early myogenic differentiation and open new ways for targeting the BMP 
pathway in muscle regeneration.
Cellular growth and differentiation are regulated by a multitude of distinct signalling pathways. Crosstalk between 
these pathways is indispensable to ensure a balanced adaptation to certain signalling inputs thereby facilitating 
specificity of signalling responses.
The Insulin Receptor Substrate 4 (IRS4) belongs to the Insulin Receptor Substrate (IRS) family of scaffold 
proteins and provides docking sites for various signalling proteins1. Similar to other IRS family members, IRS4 
was reported to associate with phosphatidylinositol-3-kinase (PI3K) and Growth factor receptor-bound protein 
2 (Grb2)2, to mediate GLUT4 translocation3 and to regulate cell proliferation4–6. There is, however, increasing 
evidence that IRS4 displays distinct signalling features since it does not interact with either SHP-2 or phospholi-
pase Cγ2 nor does it trigger cell survival in myeloid progenitor cells7. Some studies even suggest a role for IRS4 in 
suppressing the function of other IRS proteins in IGF1-mediated signalling8. Moreover, IRS4 was reported to be 
no substrate for the insulin receptor in muscle tissue9. In contrast to IRS1/2, IRS4 is expressed in a tissue-specific 
manner, predominantly in brain, kidney and skeletal muscle4, 9, 10. This could explain why mice lacking IRS4 show 
only mild defects in growth and glucose homeostasis11. Taken together, the physiological function and relevance 
of IRS4 still remain elusive.
Bone Morphogenetic Proteins (BMPs) are pleiotropic cytokines belonging to the Transforming Growth 
Factor-β (TGF-β) superfamily. They fulfil various cellular functions both during embryonic development and 
in adult tissue homeostasis by regulating distinct processes in a context-specific manner12, 13. BMPs signal via 
binding to heteromeric complexes of two types of transmembrane serine/threonine kinase receptors, the BMP 
type I (ACVRI, BMPRIA, BMPRIB) and type II receptors (ActRIIa, ActRIIb, BMPRII). Upon ligand binding the 
activated type I receptor kinase phosphorylates cytosolic receptor-regulated Smads1/5/8 (R-Smads). This in turn 
induces their oligomerisation with the common-mediator Smad4 (co-Smad) followed by subsequent nuclear 
translocation and transcriptional regulation of specific BMP/Smad target genes like inhibitors of differentiation 
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(IDs)14, 15. Besides the canonical Smad pathway, BMPs induce non-Smad signalling like Mitogen-activated protein 
kinases (MAPK) such as p38, JNK and ERK but also PI3K/Akt-mediated routes16. Since malfunction of BMP sig-
nalling is intimately linked with severe diseases including cardiovascular and musculoskeletal disorders, cancer 
and fibrosis17, tight regulation and fine-tuning are indispensable. This may occur at multiple levels of the signal-
ling cascade for instance by extracellular antagonists, co-receptors or by receptor internalisation18. Another layer 
of regulation is achieved by cytosolic proteins binding to the BMP receptors like LIM kinase 1 (LIMK1) or cyclic 
guanosine-monophosphate (cGMP)-dependent kinase I (cGKI)19, 20. Also the BMP pathway crosstalks to other 
signalling pathways, e.g. Hippo and MAPK21–23 thereby regulating cell growth and differentiation.
Here, we present IRS4 as a novel player in the BMP pathway, which physically interacts with the BMP receptor 
BMPRII and affects BMP-induced signalling in myoblasts. We show that IRS4 interferes with BMP signal trans-
duction by impinging on the abundance of its downstream signalling component Smad1. The IRS4-dependent 
decrease of Smad1 protein is linked to enhanced ubiquitination and subsequent degradation of Smad1 resulting 
in its reduced transcriptional activity. In addition, IRS4 affects the non-Smad signalling branch by promoting Akt 
signalling in muscle cells. Furthermore, our data provide clear evidence that IRS4 is expressed in myoblasts dur-
ing mouse limb development as well as in postnatal satellite cells suggesting its involvement in myogenesis. We 
show that the BMPRII interacting IRS4 serves as a novel platform for inhibition of BMP/Smad signalling along 
with an activation of the PI3K/Akt axis to promote differentiation of precursor cells to the myogenic lineage.
Results
IRS4 interacts with BMPRII in a ligand-independent manner at the plasma membrane. IRS 
proteins are crucial mediators of various cellular functions. They exhibit a common architecture comprised of 
conserved pleckstrin homology (PH) as well as phosphotyrosine binding (PTB) domains and a more variable 
C-terminus containing tyrosine and serine residues which can be phosphorylated. Depending on the residues 
phosphorylated and the downstream effectors engaged, specific signalling outcomes are initiated. Apart from 
general physiological functions such as glucose metabolism, mitogenesis and survival, IRS proteins exert more 
particular functions in a tissue-specific context24–26 (Fig. 1a). The relevance of Insulin Receptor Substrate 4 (IRS4) 
however has not been clarified yet. Here, we aim to decipher its function as a novel modulator of BMP signalling.
A tandem affinity-based mass spectrometry approach was used to screen for proteins interacting with BMP 
receptors. We identified several BMP receptor type II (BMPRII) associated proteins, among these IRS4, which 
co-precipitated with BMPRII long form both in the absence and presence of BMP2 (Supplementary Fig. S1a). 
BMPRII exists in two splice variants; a short form (BMPRII-SF) ending after the kinase domain and a long form 
(BMPRII-LF), the prevalent form in most cell types27. To confirm the interaction, co-immunoprecipitation exper-
iments using HEK293T cells were performed. HA-tagged BMPRII long form (HA-BMPRII-LF) co-precipitated 
with endogenous IRS4 as well as with myc-tagged IRS4, whereas in control samples the receptor was not detected 
(Fig. 1b and c). To analyse whether interaction with BMPRII is specific to IRS4, IRS1–3 were included into the 
studies. We observed that in addition to IRS4 also IRS2 interacts with BMPRII-LF (Supplementary Fig. S1b), 
which might be explained by the slightly higher sequence homology of IRS2 with IRS4 compared to the other IRS 
proteins1. Noteworthy, the interaction of IRS4 with BMPRII-LF was independent of BMP2 stimulation (Fig. 1d) 
indicating that scaffold protein IRS4 is constitutively bound to the receptor. To investigate whether IRS4 interacts 
with BMPRII at the plasma membrane, cell surface biotinylation assays were performed in transfected HEK293T 
cells. Indeed, more IRS4-myc was precipitated when HA-BMPRII-LF was co-expressed in these cells (Fig. 1e, 
compare lanes 1 and 3 upper panel). The faint band appearing when no HA-BMPRII-LF was co-expressed 
(Fig. 1e, lane 3 upper panel) can be assigned to the binding of IRS4 to other endogenous surface receptors like the 
insulin, FGF or leptin receptors28–30, which were biotinylated as well. In cells expressing IRS1-myc co-expression 
of BMPRII-LF did not lead to increased signals (Fig. 1e, compare lanes 5 and 7 upper panel) confirming the 
results from Supplementary Fig. S1b.
IRS4 was identified as a 160 kDa protein undergoing rapid tyrosine phosphorylation upon insulin stimula-
tion1. Using a pan-phospho tyrosine antibody, we found strongly increased tyrosine phosphorylation of precipi-
tated IRS4-myc after BMP2 stimulation (Fig. 1f), which provides additional evidence for the role of IRS4 in BMP 
signalling.
Taken together, IRS4 constitutively associates with BMPRII at the plasma membrane and BMP-mediated 
receptor activation induces tyrosine phosphorylation of IRS4.
Mapping of the BMPRII binding site at IRS4. To further characterise the IRS4/BMPRII interaction and 
to elucidate which region of IRS4 is involved in binding to BMPRII, a series of IRS4 truncations was generated 
(Fig. 1g). Truncations lacking parts of the C-terminal portion, the PH or PH and PTB domains were charac-
terized for interaction with BMPRII-LF. Serial truncations of IRS4 from the C-terminus to amino acid residue 
604 and the IRS4 wild type (WT) revealed clear and robust binding to BMPRII-LF (Fig. 1h). Deletion of the PH 
domain (ΔPH) or deletion of PH and PTB domain (ΔPH_PTB) abolished the association. Using the shortest 
truncations containing only the PH domain (E201) or only the PH and PTB domains (Y337), binding to BMPRII 
was severely affected. Together, these results imply that the PH domain as well as a C-terminal region distal of the 
PTB domain are required to foster the interaction with BMPRII.
IRS4 expression causes a decrease in Smad1 protein levels. To investigate the impact of IRS4 on 
BMP signalling, we used C2C12 myoblast cells which, in contrast to HEK293T cells, do not express IRS4 endog-
enously (Supplementary Fig. S2a). To examine the role of IRS4 in BMP-induced phosphorylation of Smads, cells 
were co-transfected with YFP-Smad1 and IRS4-myc. The molecular weight shift of YFP-fused Smad1 compared 
to endogenous Smad1/5/8 enables identification of transfected cells, thus allowing a selective analysis. We found 
that expression of IRS4-myc led to reduced BMP2-induced YFP-Smad1 phosphorylation compared to mock 
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Figure 1. IRS4 interacts with BMPRII-LF in a ligand independent manner at the plasma membrane. (a) 
Scheme depicting the IRS protein domain structure, prominent interacting as well as modifying proteins 
and so far described cellular functions; the main IRSs for the respective functions are represented in bold 
letters. PH = pleckstrin homology domain; PTB = phosphotyrosine binding domain (b,c) IRS4 interacts with 
BMPRII-LF. Transfected HEK293T cells were subjected to immunoprecipitation using α-IRS4 (left) and α-myc 
(right) antibodies. Immunoprecipitates (IP) and total cell lysate (TCL) were analysed by Western blotting 
using indicated antibodies. Incubation with beads only served as IP control. (d) The IRS4/BMPRII interaction 
is ligand-independent. Transfected HEK293T cells were stimulated with 10 nM BMP2 for indicated times. 
IRS4-myc was immunoprecipitated; precipitates and TCL were analysed by Western blotting using indicated 
antibodies. Incubation with beads only served as IP control. (e) IRS4 interacts with cell surface exposed 
BMPRII-LF. Transfected HEK293T cells were incubated with biotin solution to label surface receptors followed 
by pull-down using streptavidin coupled beads. Precipitates and TCL were subjected to Western blotting using 
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transfected control cells. Concurrently, total YFP-Smad1 protein levels were considerably decreased, which might 
account for the reduced pYFP-Smad1 levels (Fig. 2a). This finding was substantiated on the level of endogenous 
Smads using flow cytometry measurements enabling the analysis of transfected cells via specific cell gating. The 
IRS4-myc-positive gated cell population revealed a marked reduction of endogenous Smad1. This effect was 
specific to IRS4 as it was not observed for IRS1-myc-positive cells (Fig. 2b). BMP2 stimulation had no impact on 
the IRS4-mediated Smad1 decrease (Supplementary Fig. S2b). Endogenous Smad5 levels as well as FLAG-Smad5 
levels were not affected by IRS4-myc expression (Supplementary Fig. S2c and d) indicating a mechanism specific 
to Smad1. Overall, IRS4 affects basal Smad1 but not Smad5 protein levels which in turn reduces the Smad1 pool 
available for ligand-induced phosphorylation.
The IRS4-dependent decrease of Smad1 protein is due to enhanced ubiquitination and pro-
teasomal degradation. To understand the underlying mechanism of the IRS4-dependent Smad1 reduc-
tion in more detail, transfected C2C12 cells were treated with cycloheximide to study Smad1 stability/turnover 
via inhibition of de novo protein synthesis. Cycloheximide treatment caused a more pronounced reduction of 
YFP-Smad1 protein in IRS4-myc expressing cells when compared to control cells, while FLAG-Smad5 levels 
remained unaffected (Fig. 2c and Supplementary Fig. S2d). Analogous experiments using MG132 to inhibit pro-
teasomal activity revealed a rescue of the IRS4-induced YFP-Smad1 decrease almost comparable to control cells 
(Fig. 2d). In vitro ubiquitination assays demonstrated enhanced poly-ubiquitination of Smad1 upon IRS4 expres-
sion (Fig. 2e, compare lanes 2, 5 and 6). These results strongly suggest that IRS4 supports poly-ubiquitination of 
Smad1 consequently resulting in its increased proteasomal degradation.
Next, we investigated whether IRS4 interacts with Smad1 and found that FLAG-Smad1 
co-immunoprecipitated with IRS4-myc, which was even enhanced by BMP2 stimulation (Fig. 2f). We conclude 
that IRS4 by binding to Smad1 promotes its ubiquitination thus targeting Smad1 for degradation. The IRS4/
BMPRII interaction might facilitate association with Smad1 by ensuring a close proximity of both proteins par-
ticularly upon BMP2 stimulation.
IRS4 reduces the transcriptional activity of Smad proteins. To analyse the functional implication of 
the IRS4-mediated Smad1 degradation on the expression of BMP/Smad target genes, reporter gene assays were 
performed using luciferase under the control of a BMP-responsive element (BRE) derived from the murine Id1 
promoter31. Expression of IRS4-myc led to significant attenuation of BRE reporter gene activity in response to 
BMP2 after 6 h (Supplementary Fig. S2e). This effect was even more pronounced after 24 hours of BMP2 stimula-
tion (Fig. 3a). Expression of IRS1-3 did not alter BMP2-induced Smad-dependent transcriptional activity (Fig. 3a 
and Supplementary Fig. S2f), again underlining the IRS4-specific effect. Moreover, IRS4-myc expression resulted 
in decreased ID1 protein levels compared to control cells (Supplementary Fig. S2g). Taken together, the observed 
reduction of Smad1 protein in the presence of IRS4 diminishes BMP/Smad-mediated transcription.
To characterise the mechanism of interference in more detail and to gain insights into the domains of IRS4 
responsible for these effects, the aforementioned IRS4 truncations were included in functional studies (Fig. 1g). 
Myc-tagged E1189- and A1174 truncations inhibited BRE reporter gene activity comparable to IRS4-myc wild 
type, while the V906 truncation showed a slightly stronger inhibition after BMP2 stimulation. In contrast, the 
other truncations tested did not affect BMP2-induced Smad-dependent transcriptional outcome (Fig. 3b and 
Supplementary Fig. S2h).
Our data suggest that it is the C-terminal portion of IRS4, which is important for the protein’s impact on BMP 
signalling. In addition, the PH domain turned out to be crucial for the IRS4-mediated inhibition of BMP/Smad 
signalling which is in accordance with our interaction studies indicating its requirement for the association with 
BMPRII.
Expression of IRS4 is linked to strong Akt activation. Next, we studied the impact of IRS4 on BMP/
non-Smad signalling. While expression of IRS4-myc and IRS1-myc did not affect BMP2-induced phosphoryla-
tion of MAPK p38, there was a strong and ligand-independent phosphorylation of Akt at residue Ser473 in the 
presence of IRS4-myc only (Fig. 3c). The effect of IRS4 on Akt activation has been described previously for var-
ious cancer cell lines, fibroblasts, myeloid progenitor cells, HepG2 and HEK293T cells6, 7, 32–35. Here, we demon-
strate the link between IRS4 and Akt signalling in muscle precursor cells. Expression of IRS4-myc in C2C12 
cells induced phosphorylation of Akt at residue Thr308 and Ser473, critical for full activation of Akt36 (Fig. 3d). 
Downstream targets of Akt such as p70S6K and GSK3β were phosphorylated as a consequence of IRS4-myc 
expression. We conclude, that the IRS4-dependent decrease of Smads transcriptional activity along with a strong 
activation of the Akt pathway might have an impact on the differentiation of myogenic precursor cells.
indicated antibodies. (f) IRS4 is tyrosine phosphorylated upon BMP2 stimulation. Transfected HEK293T cells 
were stimulated with 10 nM BMP2 for indicated times; 100 nM insulin (Ins) served as positive control. IRS4-
myc was immunoprecipitated; precipitates and TCL were analysed by Western blotting. Quantification depicts 
pan pY signals normalised to precipitated IRS4-myc. Incubation with beads only served as IP control. (g) 
Scheme depicting IRS4 WT and truncated mutants thereof. Interaction (✓) or no interaction (x) is indicated 
on the left side; n refers to the number of performed experiments. (h) Mapping of the BMPRII binding region 
at IRS4. Transfected HEK293T cells were subjected to immunoprecipitation using an α-myc antibody. The 
expected molecular weight of IRS4 wild type (WT) and truncations are indicated by arrows. To analyse different 
proteins in the same samples simultaneously, membranes were cut accordingly and incubated with respective 
antibodies separately. For a clear and concise data presentation, displayed blots were cropped slightly.
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Figure 2. IRS4 causes reduction of Smad1 levels. (a) IRS4 expression reduces Smad1 protein. Transfected 
C2C12 cells were stimulated with 10 nM BMP2 for the indicated times. Lysates were analysed by Western 
blotting using indicated antibodies. (b) IRS4 interferes with endogenous Smad1 protein levels. Transfected 
C2C12 cells were gated on myc-positive single cells (blue and red curve) via flow cytometry and endogenous 
Smad1 levels were analysed. Median fluorescence intensity (MFI) values of myc-positive cells were compared 
to those of all cells (grey curves). Bar charts represent means ± SD of 3 independent experiments. (c,d) The 
Smad1 decrease is mediated via proteasomal degradation. Transfected C2C12 cells were incubated with 5 µg/
ml cycloheximide (c) or 10 µM MG132 (d) for 6 h; ethanol and DMSO were applied as respective vehicle 
control. Lysates were subjected to Western blotting. Quantification depicts total YFP-Smad1 level normalised 
to β-actin or GAPDH relative to β-galactosidase. Bar charts represent mean ± SD from 3 independent 
experiments. (e) IRS4 enhances ubiquitination of Smad1. Transfected HEK293T cells were incubated with 
5 µM MG132 overnight and subjected to immunoprecipitation of FLAG-Smad1 using an α-FLAG antibody. 
Immunoprecipitates and TCL were analysed by Western blotting using indicated antibodies. Incubation with 
beads only served as IP control. (f) IRS4 interacts with Smad1. Transfected HEK293T cells were stimulated with 
10 nM BMP2 for indicated times. Immunoprecipitation was performed using α-myc antibody; precipitates and 
TCL were analysed by Western blotting. Incubation with beads only served as IP control. To analyse different 
proteins in the same samples simultaneously, membranes were cut accordingly and incubated with respective 
antibodies separately. For a clear and concise data presentation, displayed blots were cropped slightly.
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IRS4 is expressed in developing mouse limbs, primary foetal mouse myoblasts and postnatal 
satellite cells. To confirm our data in vivo, we next analysed the expression of IRS4 in developing mouse 
limbs. Using whole limb mRNA, Irs4 expression was detectable in limb mesenchyme and was upregulated during 
embryonic myogenesis between stage E10.5 and E13.5, whereas at E14.5 mRNA levels were strongly decreased. 
IRS4 showed robust expression again in foetal limb tissue at E18.5 (Fig. 4a and Supplementary Fig. S3a). While 
the expression of the early myogenic markers Pax7 and Myf5 decreased at later developmental stages (Fig. 4a 
and Supplementary Fig. S3b and c), MyoG levels increased over time. Remarkably, Myog expression revealed a 
similar trend as IRS4 mRNA levels (Fig. 4a and Supplementary Fig. S3a and d). Next, we analysed which limb 
mesenchymal cells express IRS4 in situ via immunostaining on tissue sections, however of several tested antibod-
ies none provided reliable results. We therefore isolated primary myoblasts from E18.5 developing mouse limb 
muscles which showed clear expression of Irs4 mRNA (Fig. 4b). For immunolabelling, cells were immediately 
cytospun and fixed to reflect the endogenous in vivo situation as closely as possible and to avoid culturing arte-
facts. After cytospin, cells were subjected to immunofluorescence staining for IRS4, MyoD and Pax7. As expected 
the cells constituted a mixed population with myoblasts positive for MyoD and/or Pax7. Cells positive for nuclear 
MyoD or Pax7 staining revealed a co-expression of cytosolic IRS4 protein (Fig. 4c, see arrows). These findings 
were further confirmed in mouse satellite cells isolated at postnatal day 7. Cultivation of these cells induced 
Figure 3. IRS4 reduces transcriptional activity of Smad proteins and initiates Akt pathway activation. (a,b) 
IRS4 but not IRS1 affects Smads transcriptional activity. C2C12 cells transfected with BRE-luc, RL-TK and 
IRS1-myc or IRS4-myc (a), truncated mutants thereof (b) or β-galactosidase as indicated were stimulated 
with 5 nM BMP2 for 24 h. Bar charts depict means ± SD of RLU from triplicate measurement relative to 
β-galactosidase representative for 3 independent experiments. RLU = relative luciferase units (BRE-luc/RLTK-
luc). (c,d) Expression of IRS4 but not IRS1 induces activation of Akt signalling. Transfected C2C12 cells were 
stimulated with 10 nM BMP2 for indicated times. Lysates were subjected to Western blotting using indicated 
antibodies. To analyse different proteins in the same samples simultaneously, membranes were cut accordingly 
and incubated with respective antibodies separately. For a clear and concise data presentation, displayed blots 
were cropped slightly.
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commitment into myoblasts characterised by upregulation of Myod mRNA as early differentiation marker and 
decrease of the satellite cell marker Pax7. Noteworthy, Irs4 levels were also increased during cultivation correlat-
ing with Myod expression. In myoblasts at the brink of terminal differentiation, i.e. high in Myod and initiating 
Myogenin expression, Irs4 expression peaked. After that IRS4 expression decreased again in terminally differen-
tiated myoblasts/myotubes exclusively positive for Myogenin (Fig. 4d). In line, immunofluorescence stainings 
showed co-expression of IRS4 with both Pax7 and MyoD in cultured satellite cells. In contrast, IRS4 protein was 
not detected in myotubes (Fig. 4e). Our data demonstrate for the first time co-expression of IRS4 with skeletal 
muscle markers in intact, freshly isolated myogenic cells.
Figure 4. In vivo expression of IRS4 in mouse limbs, primary myoblasts and satellite cells. (a) IRS4 is 
expressed during mouse limb development. RNA from mouse limbs of indicated embryonic developmental 
stages was isolated, reverse-transcribed and subjected to gene expression analyses via qRT-PCR. Data points 
summarise triplicate measurements and depict mean normalised expression (MNE) ± SEM representative 
for 2 independent experiments. (b) IRS4 is expressed in cells freshly isolated from foetal limb skeletal 
muscle. Primary mouse myoblasts were isolated from E18.5 limb muscles. PCR shows IRS4 transcript in 
myoblasts; E14.5 embryonic brain tissue served as positive control, WT1 fat cells as negative control. (c) 
Immunofluorescence staining of primary E18.5 mouse myoblasts using indicated specific antibodies shows 
IRS4/MyoD and IRS4/Pax7positive cells (see arrows); nuclei were stained using DAPI. (d) IRS4 is expressed 
in cultured satellite cells. Mouse satellite cells were isolated from P7 limb muscles, cultured for the indicated 
days and subjected to PCR analyses. Embryonic forebrain served as positive control. (e) Immunofluorescence 
staining of cultured mouse satellite cells using indicated specific antibodies reveals expression of IRS4 in 
postnatal muscle precursor cells; nuclei were stained using DAPI.
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IRS4 enhances the expression of myogenic markers thereby triggering myogenesis. Based on 
the endogenous expression of IRS4 in mouse muscle precursor cells and taking the prominent role of Akt and 
BMP signalling in regulating myogenesis into account, we next investigated the effect of IRS4 in myoblast dif-
ferentiation. We performed reporter gene assays using luciferase under the control of the myogenin promoter 
(Myg-luc)37. Myogenin is pivotal for terminal differentiation of committed myoblasts into contractile myotubes38. 
Expression of IRS4, but not IRS1, strongly increased the Myg-luc reporter activity (Fig. 5a). While BMP2 treat-
ment during differentiation considerably inhibited reporter activity in control cells, IRS4 transfected cells were 
still capable of inducing Myg-luc transcription. Using the IRS4 truncations, we found that the E1189 and A1174 
truncations promoted Myg-luc activity similar to wild type IRS4, while the V906 variant of IRS4 showed an 
increased activity with an even more pronounced positive effect on Myg-luc expression as compared to wild type 
(Fig. 5b). The other truncations showed no impact on Myg-luc reporter activity. These data are in line with the 
Figure 5. IRS4 enhances expression of myogenic markers and promotes myogenesis. (a,b) IRS4 but not 
IRS1 affects Myg-luc expression. C2C12 cells transfected with the Myg-luc reporter and indicated constructs 
were differentiated with or without 5 nM BMP2. Bar charts depict means ± SD of firefly luciferase activity 
from triplicate measurements representative for 3 independent experiments. (c) IRS4 enhances expression of 
myogenic markers. Transfected C2C12 cells were differentiated with or without 5 nM BMP2 for indicated times. 
Lysates were subjected to Western blotting using indicated antibodies. Dashed lines indicate the exclusion 
of irrelevant lanes from the same membrane (d) IRS4 triggers myogenesis. Transfected C2C12 cells were 
differentiated with or without 5 nM BMP2. Myosin heavy chain (MHC) was stained using a specific antibody; 
nuclei were stained using DAPI. Images were quantified using ImageJ. Bar chart depicts means ± SD of at least 
60 images per condition derived from 4 independent experiments. To analyse different proteins in the same 
samples simultaneously, membranes were cut accordingly and incubated with respective antibodies separately. 
For a clear and concise data presentation, displayed blots were cropped slightly.
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findings derived from the BRE-luc studies (Fig. 3b), i.e. those IRS4 variants that revealed an inhibitory effect on 
BMP/Smad signalling were demonstrated to promote myogenic differentiation.
To further substantiate our evidence that IRS4 counteracts BMP action and is involved in myogenic differen-
tiation, the expression of the myogenic marker proteins caveolin-3, MyoG and myosin heavy chain (MHC) was 
analysed. Myogenic markers were stronger expressed in IRS4-myc expressing compared to control cells dur-
ing the course of differentiation already after two days (Fig. 5c; left panels). While BMP2 stimulation almost 
completely abolished expression of myogenic markers in control cells, IRS4-myc wild type expressing cells still 
displayed remarkable expression of analysed marker proteins (Fig. 5c; right panels). The pro-myogenic effect of 
IRS4 could also be demonstrated by immunofluorescence staining of MHC in C2C12 cells after three days of 
differentiation. IRS4-myc expression promoted the formation of longer and thicker, i.e. hypertrophic myotubes in 
the absence of exogenous BMP stimulation. In BMP2-stimulated samples IRS4 was capable of rescuing myogenic 
differentiation to some extent (Fig. 5d). The enhanced differentiation as indicated by MHC-positive myotubes 
was confirmed by quantification of the overall MHC-positive area (Fig. 5d, bar chart).
Targeted knockdown of IRS4 in human myoblasts leads to enhanced BMP signalling 
and impaired myogenic differentiation capacity. To complement our results obtained from 
gain-of-function experiments in IRS4 overexpressing C2C12 cells, we performed loss-of-function experiments 
in immortalised human myoblasts39. Initially, these cells were characterised with regard to their BMP signalling 
properties. As depicted in Supplementary Fig. S4a, immortalised human myoblasts express BMP type I and type 
II receptors. Stimulation with BMP2 induced Smad1/5/8 phosphorylation and induction of ID1 mRNA, but also 
phosphorylation of MAPK p38 (Supplementary Fig. S4b and c). BMP2 treatment efficiently prevented these 
cells from differentiating into myotubes (Supplementary Fig. S4d). Next, endogenous expression of IRS4 was 
verified via flow cytometry measurements (Supplementary Fig. 4e). Using co-immunoprecipitation analyses, we 
demonstrated endogenous interaction of IRS4 with BMPRII and Smad1 (Fig. 6a and c). This was validated by 
an in situ proximity ligation assay (PLA) clearly visualising the IRS4/BMPRII and IRS4/Smad1 association in 
intact myoblasts (Fig. 6b and d). To further examine the biological relevance of IRS4 in both BMP signalling 
and in myogenic differentiation, IRS4 was depleted by siRNA-mediated knockdown. Verification of knockdown 
efficiency clearly demonstrated depletion of both IRS4 mRNA and protein (Supplementary Fig. 4f). Knockdown 
of IRS4 revealed a marked increase of ID1 mRNA and protein during the course of myogenic differentiation par-
ticularly at day 0. BMP2 stimulation induced ID1 expression whereas IRS4 depleted cells showed an even stronger 
induction (Fig. 6e and g). MyoG and MHC, which were upregulated during myogenesis and repressed by BMP2 
addition, were only barely detectable when IRS4 was depleted (Fig. 6f and g). Comparably, IRS4 knockdown in 
either primary mouse foetal myoblasts or postnatal satellite cells caused decreased myotube formation as assessed 
by MHC and actin staining (Supplementary Fig. S5a and b). Furthermore, depletion of IRS4 led to reduced 
phosphorylation of Akt at any time point analysed independent of ligand addition, while control cells displayed 
a higher pAkt level especially after induction of differentiation. Interestingly, we found that IRS4 protein was 
successively downregulated during myogenesis. In contrast, protein levels remained almost unchanged when 
myogenic differentiation was prevented by BMP2 treatment (Fig. 6h). This is in accordance with our findings in 
satellite cells in which IRS4 was expressed during proliferation but not in differentiated myotubes (Fig. 4d and e).
Taken together, our data demonstrate that IRS4 is a pivotal factor in myogenesis. IRS4 is expressed in myo-
blasts during mouse limb development and its expression level strongly correlates with the cells’ state of differen-
tiation. Furthermore, IRS4 depletion resulted in impaired myogenic differentiation capacity. We propose that this 
is due to IRS4-mediated downregulation of BMP/Smad concomitant to enhanced PI3K/Akt signalling.
Discussion
BMP ligands elicit critical biological outcomes by initiating both the canonical Smad pathway as well as 
non-Smad mediated routes strongly depending on the cellular context. Considering the functional diversity of 
BMPs, BMP signalling is subject to tight regulation ensuring a concise and balanced propagation of signalling 
responses. Hence, a multitude of elaborate regulatory mechanisms facilitate physiological BMP functions. In the 
last years, various BMP receptor interacting proteins have been reported to affect BMP signal transduction by 
distinct modes of action19, 20, 40–42. Still, it is of great importance to identify modulatory proteins to explain specific 
cell-context dependent actions of this growth factor family. Analysing regulatory networks provide the knowledge 
of subtle fine-tuning, signalling crosstalk and specificity, which is of crucial relevance particularly for understand-
ing complex processes such as tissue regeneration.
Here, we present Insulin Receptor Substrate 4 (IRS4) as a novel regulatory factor in the BMP pathway and 
provide a new molecular mechanism of this scaffold protein. We show that IRS4 interferes with BMP signalling 
by interacting with the BMP receptor BMPRII and by promoting ubiquitination and proteasomal degradation of 
specifically Smad1. Concomitantly, IRS4 activated the PI3K/Akt axis which in concert with decreased BMP/Smad 
signalling enhanced myogenic differentiation of muscle precursor cells (illustrated in Fig. 7).
Within a proteomic screen for novel proteins interacting with BMPRII, we identified the adapter protein IRS4. 
We used different immunoprecipitation-based approaches and in situ PLA to demonstrate that the interaction 
of both proteins was very robust and occurred at the plasma membrane. Noteworthy, the interaction was inde-
pendent of BMP2 stimulation. In contrast, other BMPRII interacting proteins like cGKI and Tribbles-like protein 
3 (Trb3) are reported to dissociate from the receptor upon ligand addition either to enhance transcriptional 
responses by binding to activated Smads or to trigger degradation of Smurf1 thus potentiating the BMP/Smad 
pathway20, 43. Interaction of the rare PI3K regulatory subunit p55γ with BMPRII is enhanced by BMP2 leading to 
ligand-induced chemotaxis of progenitor cells41. IRS4 as a classical scaffold protein does not exhibit any intrinsic 
catalytic activity but rather serves as binding hub between cell surface receptors and downstream signalling com-
ponents. We propose that even though binding to BMPRII is not altered by BMP2, ligand addition might modify 
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Figure 6. Targeted IRS4 knockdown causes impaired myogenic differentiation capacity in human myoblasts. 
(a,c) Endogenous interaction of IRS4 with BMPRII and Smad1. Human myoblasts were subjected to 
immunoprecipitation using an α-IRS4 antibody. Immunoprecipitates (IP) and total cell lysate (TCL) were 
analysed by Western blotting using indicated antibodies. Incubation with beads only served as IP control. 
(b,d) In situ proximity ligation assay (PLA) of IRS4 and BMPRII or Smad1. Human myoblasts were subjected 
to in situ PLA (green signal) to visualize the endogenous association of IRS4 with BMPRII (b) or Smad1 (d); 
nuclei and the actin cytoskeleton were stained using DAPI and Phalloidin594. Relevant controls are depicted 
in Supplementary Fig. S4g. (e–g) IRS4 knockdown affects myogenesis and BMP signalling. Human myoblasts 
were transfected with siRNA targeting either nonspecific sequences (scr si) or human IRS4 (hIRS4 si) and 
differentiated with or without 10 nM BMP2 for indicated times. Gene expression was analysed by qRT-PCR. 
Bar charts summarise triplicate measurements and depict MNE ± SEM representative for 3 independent 
experiments. (g) Protein lysates were subjected to Western blotting using indicated antibodies. (h) IRS4 
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the overall platform of binding sites within IRS4. Upon stimulation with insulin and leptin, IRS4 was reported 
to be tyrosine phosphorylated thereby giving rise to binding of e.g. SH2 domain containing proteins like PI3K 
and Grb22, 29. Interestingly, we found that IRS4 was also phosphorylated on tyrosine residues when cells were 
stimulated with BMP2. This might provoke engagement of a different subset of downstream proteins hence influ-
encing signalling outcome. Furthermore, this finding might point to the dual kinase activity of BMPRII, which 
has already been proposed41, 44 and was described for the related TGFβ receptor type I and II45, 46. It is tempting 
to speculate that other BMP receptor-associated kinases such as c-kit or c-src mediate BMP2-induced tyrosine 
phosphorylation of IRS447–49.
Mapping of the BMPRII binding site at IRS4 revealed the PH domain and a C-terminal region distal of the 
PTB domain to mediate the association. We assume that the PH domain is required to recruit the protein to the 
plasma membrane by binding to phospholipids thereby enabling close proximity to BMPRII, while the associa-
tion with the receptor is mediated via the C-terminus. Beyond, consideration might be given that the PH domain 
is capable of directly binding to upstream receptors as suggested by a study mapping the IRS4 interaction with 
the leptin receptor29. IRS proteins bind to pTyr within receptors via their PTB domain25. Recently, the BMPRII 
was shown to be tyrosine phosphorylated41 thus providing a pivotal feature for interacting with IRS4. Still, based 
on our data, we cannot assure that the PTB domain is needed for the association or comment on whether the 
interaction is direct or mediated via any intermediate proteins linking IRS4 to BMPRII.
To investigate the functional implication of the IRS4/BMPRII interaction on BMP signalling, kinetic analyses 
and reporter gene assays were performed. We found that expression of specifically IRS4 caused decreased total 
Smad1 protein levels in C2C12 cells. We provide clear evidence for a mechanism involving IRS4-driven enhanced 
poly-ubiquitination and proteasomal degradation which appeared to be Smad1-specific since Smad5 levels were 
not affected. These findings suggest that Smad1 and Smad5 display divergent roles in propagating BMP signal-
ling in C2C12 cells, as Smad5 was not sufficient to compensate for the loss of Smad1. BMP Smads are highly 
homologous and exert overlapping functions referring to different studies50–55. However, evidence emerges that 
Smads do not exclusively function redundantly and regulate distinct cellular functions depending on the cellular 
context56–58. Various modes of interference with R-Smad activity such as C-terminal dephosphorylation catalysed 
by distinct phosphatases40, 59, sequential phosphorylation in the Smad linker region by MAPK/CDKs and GSK3β 
triggering poly-ubiquitination and degradation60 but also inhibitory Smads6/7 targeting R-Smads for degradation 
in a negative feedback manner61, 62 are well described. Here, we demonstrate a novel regulatory mechanisms lead-
ing to IRS4-mediated reduced Smad1 stability and thus decreased overall Smad1 pool in the absence of ligand. 
We speculate that scaffold protein IRS4 does not only interact with BMPRII and Smad1 but also associates with 
and thereby recruits components intimately linked to the ubiquitination/proteasomal machinery. In conclusion, 
IRS4 expression fundamentally reduces steady-state Smad1 protein resulting in decreased transcriptional activity 
of Smads and thus repressed BMP/Smad signalling outcome.
In recent years, studies on the role of BMPs in muscle maintenance and regeneration emerged remarkably. 
For example, it has been described that BMP signalling promotes proliferation of muscle precursor cells, while 
differentiation is rather inhibited14, 63–66. This blockage of differentiation is mediated by BMP-induced ID proteins, 
which bind to E-proteins thereby preventing the formation of transcriptional active heterodimers with myogenic 
regulatory factors67, 68. Furthermore, the BMP/Smad axis has been shown to exert positive effects on the regu-
lation of muscle mass thus emphasizing a critical role for BMP signalling in muscle homeostasis69, 70. We found 
that expression of IRS4, by counteracting BMP/Smad signalling, efficiently triggered myogenic differentiation of 
C2C12 cells. Concurrently, IRS4 knockdown in human myoblasts revealed an upregulation of ID1, while myo-
genic differentiation capacity was severely impaired. We also confirmed this in primary muscle precursor cells by 
depletion of IRS4. Of note, the pro-myogenic impact of IRS4 even appeared in the absence of exogenously added 
BMP, while the medium added for differentiation might contain some BMPs. Our data strongly suggest that the 
promoting effect of IRS4 on myogenic differentiation might be a result of both inhibition of BMP/Smad signalling 
and at the same time activation of the Akt pathway. Akt is a critical player during myogenic differentiation and 
triggers protein synthesis by activating the mTOR/p70S6K axis which is pivotal for not only muscle differenti-
ation but also hypertrophy71. Simultaneously, active Akt inhibits GSK3β which itself is a potent suppressor of 
myogenesis72, 73. In line, we demonstrated that knockdown of IRS4 resulted in decreased Akt activation and lack 
of myotube formation. Noteworthy, we found IRS4 protein levels in human myoblasts to be intimately linked to 
the cells’ differentiation state: Once cells were terminally committed to the myogenic differentiation programme, 
as indicated by robust expression of Myogenin, IRS4 protein was downregulated while IRS4 level remained unal-
tered upon BMP2 treatment, indicating a critical role for IRS4 in regulating myogenic progenitor differentia-
tion. Comparable results were observed in cultured and differentiated primary satellite cells. In conclusion, the 
pro-myogenic effect of IRS4 is likely due to a combination of BMP/Smad inhibition decreasing ID1 expression 
and alleviating its inhibitory effect on myogenic regulatory factors, and in addition interference of IRS4 with 
other pathways pivotal for myogenesis, e.g. switching BMP signalling to the Akt pathway. Our study demonstrates 
the important role of IRS4 in differentiation of muscle precursors for the first time and strongly emphasizes the 
relevance of IRS4 in skeletal muscle, one of the few tissues where it has been detected4, 9. Male IRS4 knockout mice 
expression decreases during differentiation. Human myoblasts were differentiated with or without 10 nM BMP2 
for indicated times. IRS4 expression was assessed by flow cytometry using a specific antibody (solid line) or 
isotype control IgG (dotted line). Bar charts depict means ± SD of MFI values normalised to appropriate IgG 
control relative to d0 of 3 (w/o) or 2 (w/) independent experiments, respectively. To analyse different proteins 
in the same samples simultaneously, membranes were cut accordingly and incubated with respective antibodies 
separately. For a clear and concise data presentation, displayed blots were cropped slightly.
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exhibited significantly reduced weight pointing to a muscle phenotype and indicates a role for IRS4 as a regulator 
of muscle differentiation/homeostasis11. This is further supported by our in vivo expression data of IRS4 in mouse 
myoblasts during embryonic and foetal development as well as in mouse satellite cells.
Taken together, our results give the first functional evidence for IRS4 as a critical regulator of BMP/Smad and 
Akt signalling in the context of muscle differentiation. This represents a new mechanism explaining cell-context 
specific actions of BMPs as IRS4 serves as a molecular switch in early myogenic differentiation and provides 
implications in muscle regeneration and maintenance.
Methods
All methods were carried out in accordance with relevant guidelines and regulations. All experimental protocols 
were approved by named institutional and/or licensing committees.
Expression plasmids. The coding sequences of mouse IRS1/2/4 and rat IRS3 were subcloned from Addgene 
constructs (plasmid# 11374/11373/11363/11361) into the pcDNA3.1 V5/His-TOPO vector. IRS4 truncations 
were generated using the TOPO TA cloning kit (Invitrogen) according to manufacturer’s instructions. Used prim-
ers are listed in Supplementary Table S1. All constructs contain a C-terminal myc-tag.
Plasmids encoding human HA-BMPRII-LF and human Smad1 subcloned into pEYFP-C1 were described 
previously74–76. Human FLAG-tagged Smad1 and murine FLAG-tagged Smad5 were kindly provided by Peter 
ten Dijke, Leiden, Netherlands. β-galactosidase (βGal) was obtained from Harvey F. Lodish, Cambridge, MA. 
HA-ubiquitin was kindly provided by Aristidis Moustakas, Uppsala, Sweden.
Cell culture and transfection. C2C12 mouse myoblasts and HEK293T cells were cultivated in Dulbecco’s 
modified Eagle Medium (DMEM; Biochrom AG) supplemented with 10% fetal calf serum (FCS; Biochrom 
AG), 2 mM L-glutamine and penicillin (100 units/ml)/streptomycin (10 µg/ml) (PAA) at 37°C and 10% or 5% 
CO2, respectively. Immortalised human myoblasts were cultured in skeletal muscle growth medium (Provitro) 
supplemented with supplement mix (Provitro), 50 ng/ml amphotericin, 50 µg/ml gentamicin, 10% FCS, 
2 mM L-glutamine and penicillin (100 units/ml)/streptomycin (10 µg/ml) at 37°C and 5% CO2.
Figure 7. IRS4 interferes with BMP signal transduction and functions as a novel regulator of BMP signalling 
and myogenesis. IRS4 interacts with BMPRII in a ligand independent manner and affects BMP signalling 
outcomes. Presence of IRS4 in cells results in reduced Smad1 protein levels, while Smad5 levels are unaffected. 
This is due to enhanced poly-ubiquitination and subsequent proteasomal degradation of Smad1, which 
consequently results in reduced transcriptional activity of BMP Smads. In addition, IRS4 provokes activation 
of the PI3K/Akt signalling axis. Both, the IRS4-dependent inhibition of BMP/Smad signalling and the IRS4-
mediated Akt pathway activation eventually contribute to the differentiation of muscle precursor cells into the 
myogenic lineage.
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For transient transfection of HEK293T cells polyethylenimine (PEI; Sigma-Aldrich) was used. C2C12 
cells were transfected using Lipofectamine2000 (Invitrogen) according to manufacturer’s instructions. For 
siRNA-mediated knockdown of human IRS4 Lipofectamine RNAiMAX (Invitrogen) was used according to man-
ufacturer’s instructions; as control non-targeting siRNA was used (for detailed information see Supplementary 
Methods). In short, cells were transfected with 25 nM siRNA on two consecutive days and experiments were 
performed 72 h post-transfection.
Mice and isolation of primary myoblasts and satellite cells. C57BL/6 mice were kept in the animal 
facility of the Max Planck Institute for Molecular Genetics, Berlin, Germany, in accordance with legal guidelines. 
All animal procedures conducted within this study were approved by the responsible authority (Landesamt für 
Gesundheit und Soziales Berlin, LaGeSo) under license number ZH120. Timed matings were set up, and mice 
were sacrificed by cervical dislocation at indicated days of pregnancy, foetuses were sacrificed by decapitation. 
Limbs were removed and subjected to RNA extraction and subsequent quantitative real-time PCR analysis or 
isolation of primary myoblasts as described in Supplementary Methods. For the isolation of primary satellite 
cells, forelimb and hindlimb muscles from postnatal mice (day 7; P7) were used. Cell isolation, cultivation and 
differentiation are described in detail in Supplementary Methods.
Western blotting. Protein lysates were separated by SDS-PAGE and subsequently transferred on nitro-
cellulose membranes by Western blotting. Membranes were incubated with indicated primary antibodies 
overnight at 4°C according to manufacturer’s instructions. Antibodies are listed in Supplementary Methods. 
Chemiluminescent reactions were processed using Femto-Glo ECL reagents (PJK) and documented on a 
ChemiSmart5000 digital imaging system (Vilber-Lourmat). Proper loading controls (GAPDH or β-actin as indi-
cated) were examined on the same membrane. Images were quantified using Bio1D software (Vilber-Lourmat).
Co-immunoprecipitation and tyrosine phosphorylation analyses. 24 h post-transfection HEK293T 
cells were either lysed directly or starved for 6 h in serum-free DMEM and stimulated with 10 nM BMP2 or 
100 nM insulin (Roche). Immortalised human myoblasts were lysed 48 h post-seeding. Cells were lysed in RIPA 
buffer (150 mM NaCl, 50 mM Tris/HCl pH 7.4, 0.1% SDS, 0.5–1% NP-40) or TNE buffer 1 (150 mM NaCl, 20 mM 
Tris pH 7.4, 2 mM EDTA, 1% Triton X-100) supplemented with protease/phosphatase inhibitors (1 mM PMSF, 
2 mM Na3VO4, 20 mM Na4P2O7, 50 mM NaF, complete protease inhibitor cocktail (Roche)). Immunoprecipitation 
was performed with 1–4 µg anti-myc (9E10, homemade), anti-IRS4 (EP907Y) or anti-IRS4 (Santa Cruz) antibody 
overnight followed by incubation with protein A coupled sepharose beads (GE Healthcare). Samples were washed 
with lysis buffer, eluted with Laemmli buffer and subjected to Western blotting.
Surface biotinylation assay. 24 h post-transfection HEK293T cells were incubated with 0.5 mg/ml 
EZ-Link™ Sulfo-NHS-SS-Biotin solution (Thermo Scientific) followed by incubation with 50 mM Tris pH 8.0. 
Cells were lysed in RIPA buffer2 (150 mM NaCl, 25 mM Tris/HCl pH 7.4, 0.1% SDS, 0.5% NP-40) and pull-down 
of biotinylated surface proteins was performed overnight using streptavidin coupled sepharose beads (GE 
Healthcare). Samples were washed with lysis buffer, eluted with Laemmli buffer and subjected to Western blotting.
In vitro ubiquitination assay. 24 h post-transfection HEK293T cells were incubated with 5 µM MG132 
(Sigma-Aldrich) overnight. Then, cells were lysed in TNE buffer 2 (150 mM NaCl, 20 mM Tris pH 7.4, 10 mM 
EDTA, 0.5% Triton X-100, 0.5% sodium deoxycholate) supplemented with complete protease inhibitor cock-
tail and 10 mM N-ethylmaleimide. Immunoprecipitation was performed with 1 µg anti-FLAG M2 antibody 
(Sigma-Aldrich) for 4 h followed by incubation with protein A coupled sepharose beads for 1 h. Samples were 
washed excessively with lysis buffer, eluted with Laemmli buffer and subjected to Western blotting.
Investigation of Smad/non-Smad signalling and Smad protein level. 24 h post-transfection, 
C2C12 cells were starved in serum-free medium for 3 h and stimulated with 10 nM BMP2. At indicated times, 
cells were lysed in Laemmli buffer and subjected to Western blotting. To study protein turnover, cells were incu-
bated with 5 µg/ml cycloheximide (Sigma-Aldrich) or EtOH as vehicle control applied in serum-free medium for 
6 h. For inhibition of proteasomal activity, cells were incubated with 10 µM MG132 or DMSO as vehicle control 
applied in serum-free medium for 6 h.
Differentiation Assay. C2C12 cells were transfected in suspension and seeded at high density; immortal-
ised human myoblasts were seeded and transfected with siRNA as described. At confluency, differentiation was 
induced using DMEM (C2C12 cells) or OptiMEM (human myoblasts; Invitrogen) containing 2% horse serum 
(HS; PAA) in the absence or presence of 5 nM BMP2 or 10 nM BMP2, respectively. At indicated times, cells were 
harvested by addition of Laemmli buffer or RNA lysis buffer. Lysates were subjected to Western blotting or quan-
titative real-time PCR.
In situ proximity ligation assay. Immortalised human myoblasts seeded in Nunc Lab-Tec II 16-well glass 
chamber slides (Thermo Scientific) were subjected to Duolink in situ proximity ligation (Sigma-Aldrich) as previ-
ously described77 using the following antibodies: BMPRII (#612292, BD Biosciences), IRS4 EP907Y (#TA303856, 
Origene), Smad1 (ab55476, Abcam), Smad4 (#9515, Cell Signaling).
Immunofluorescence staining. C2C12 cells were transfected in suspension and seeded at high density. 
At confluency, differentiation was induced using DMEM containing 2% HS in the absence or presence of 5 nM 
BMP2. After 3 days, cells were fixed with 4% paraformaldehyde, quenched in 50 mM ammonium chloride, 
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permeabilised with 0.2% Triton X-100 in 1x PBS and blocked in 2% BSA/1% FCS. Cells were stained using 
α-myosin heavy chain (Sigma-Aldrich) and Alexa Fluor® 488 goat-α-mouse IgG (#A11001, Invitrogen) antibod-
ies. For the staining of differentiated primary foetal myoblasts or satellite cells, α-MF20 (DSHB, #AB_2147781) 
and Alexa Fluor® 488 goat-α-mouse IgG or Phalloidin594 Conjugate (sc-363795, Santa Cruz) were used. Nuclei 
were stained using DAPI (Sigma-Aldrich). Images were acquired by epifluorescence microscopy (Zeiss Axiovert 
200), processed using AxioVision software and quantified using ImageJ by creating a threshold mask for the MHC 
channel with subsequent size gating; the MHC positive area was compared to the sum image area.
Primary myoblasts derived from E18.5 foetuses or primary postnatal satellite cells were seeded on glass cover 
slips, fixed with 4% PFA and blocked with TSA puffer containing 1x PBS, 10% HS, 0.5% (w/v) blocking reagent 
(Perkin Elmer) and 0.1% Triton X-100. Cells were stained using an α-IRS4 antibody (Bioss), α-MyoD antibody 
(BD Biosciences; #554130) or α-Pax7 antibody (DSHB, #AB_528428) and Alexa Fluor 568 goat-α- rabbit or 
Alexa Fluor 488 donkey –α-mouse antibodies (#A11011; A21202, Invitrogen). Nuclei were stained with DAPI. 
Images were acquired by confocal microscopy (Zeiss LSM700) and processed using AxioVision software.
Flow cytometry. C2C12 cells were transfected as described. Where indicated, cells were starved in 
serum-free DMEM for 3 hours and stimulated with 10 nM BMP2 24 h post-transfection. Cells were harvested and 
fixed/permeabilised by incubation in ice cold 100% EtOH overnight at −20°C. After blocking in 1% BSA/1x PBS 
cells were co-stained with anti-myc tag (Cell Signaling), anti-Smad1 (Cell Signaling) or anti-Smad5 (Proteintech) 
antibodies recognized by R-phycoerythrin goat-α-mouse (#P852, Invitrogen) and Alexa Fluor®488 goat-α-rabbit 
IgG (#A11034, Invitrogen) antibodies. Immortalised human myoblasts were differentiated at confluence using 
OptiMEM containing 2% HS in the absence or presence of 10 nM BMP2. Cells were harvested and fixed/per-
meabilised using EtOH. Cells were stained using an α-IRS4 antibody (Origene) recognised by Alexa Fluor®488 
goat-α-rabbit IgG antibody (#A11034, Invitrogen); as control nonspecific isotype control IgG (#3900, Cell 
Signaling) was used. Measurements were performed using an Epics XL-MCL flow cytometer (Beckman-Coulter). 
Data were evaluated using FCS3.0 Express (Denovo Software).
Dual Luciferase Reportergene Assay. Cells were either transfected with a BMP response element 
reporter construct (BRE-luc)31 or a reporter construct containing the promoter region of myogenin (Myg-luc)37 
together with other expression constructs as indicated. A constitutively expressing construct encoding renilla 
luciferase (RL-TK; Promega) was co-transfected as internal control. The next day, cells were starved in serum-free 
medium for 3 h or with DMEM containing 0.5% FCS for 5 h and stimulated with BMP2 for 6 h or overnight. For 
the Myg-Luc assay, cells were transfected in suspension and myogenic differentiation was induced at confluency 
using DMEM containing 2% HS in the absence or presence of 5 nM BMP2; cells were incubated for 3 days. Cell 
lysis was performed using passive lysis buffer (Promega) and measurement of luciferase activity was carried out 
according to manufacturer’s instructions using a Mithras LB940 Luminometer (Berthold Detection Systems).
Quantitative real-time PCR. Total RNA extraction was performed using NucleoSpin® RNA II isolation 
kit (Machery&Nagel) according to manufacturer’s instructions; 1 µg of RNA was subjected to reverse transcrip-
tion using MMLV reverse transcriptase (Promega) and NV-oligo-dT primers (Invitrogen). Gene expression was 
assessed by quantitative PCR utilising StepOne Plus and SYBR Green PCR Master Mix (Applied Biosystems). 
Transcript expression levels were calculated as mean normalised expression (MNE) ratios referred to HPRT as 
housekeeping gene using the ΔΔCT method considering primer efficiency correction78, 79. All measurements were 
done in triplicates and CT values were determined with the StepOne Software version 2.2 (Applied Biosystems). 
Primer sequences and gene accessions numbers are depicted in Supplementary Table S2.
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